Clinical and imaging biomarkers of response to intravitreal dexamethasone implant in eyes with non-infectious uveitic macular oedema - Archive ouverte HAL
Article Dans Une Revue Eye Année : 2023

Clinical and imaging biomarkers of response to intravitreal dexamethasone implant in eyes with non-infectious uveitic macular oedema

Maria Vittoria Cicinelli
  • Fonction : Auteur
Claudia Gerosolima
  • Fonction : Auteur
Pierluigi Scandale
  • Fonction : Auteur
Sarah Touhami
  • Fonction : Auteur
Dominika Pohlmann
  • Fonction : Auteur
Amir Rosenblatt
  • Fonction : Auteur
Anat Loewenstein
  • Fonction : Auteur
Francesco Bandello
  • Fonction : Auteur
Elisabetta Miserocchi
  • Fonction : Auteur

Résumé

OBJECTIVE: To investigate clinical and spectral-domain optical coherence tomography (SD-OCT) biomarkers correlating with pre-injection visual acuity (VA), post-injection VA, and the likelihood of macular oedema (MO) regression following dexamethasone (DEX) implant injection in non-infectious uveitic (NIU) patients. METHODS: Patient data from Uveitis Services in Milan, Paris, and Berlin were analysed. Eligible participants were NIU patients aged >18 years with MO as the primary indication for DEX treatment. SD-OCT scans and clinical data were collected at the time of DEX injection (pre-injection visit) and after 3 months (post-injection visit). Multivariable regression models, adjusted for pre-injection VA and lens status, were employed to explore associations. MO regression was defined as the absence of intraretinal/subretinal fluid at the post-injection visit. RESULTS: Our analysis comprised data from 173 DEX treatments, encompassing 103 eyes from 80 patients, with 38 eyes (37%) receiving repeated DEX injections. The absence of the ellipsoid zone (EZ) layer and disorganisation of the inner retinal layers (DRIL) were associated with worse pre- (+0.19 LogMAR, 95% CI 0.01-0.38, p = 0.06, and +0.10 LogMAR, 95% CI 0.02-0.21, p = 0.01) and post-injection VA (+0.33 LogMAR, 95% CI 0.08-0.57, p = 0.01, and +0.17 LogMAR, 95% CI 0.01-0.32, p = 0.04). EZ disruption and DRIL increased significantly (p = 0.01 and p = 0.04), and the chance of gaining ≥5 letters declined in eyes undergoing repeated DEX (p = 0.002). The rate of MO regression after each DEX was 67%. Prolonged MO duration (OR = 0.75/each year, p = 0.02) was associated with reduced likelihood of MO regression. Subretinal fluid was associated with higher rate of MO regression (OR = 6.09, p = 0.01). CONCLUSION: Integrity of the inner and outer retina is associated with better visual response to DEX. Long-standing or recurrent MO is associated with less chance of both visual and anatomic response. Timely treatment is necessary to maximise the outcomes of MO in NIU patients.
Fichier principal
Vignette du fichier
BPH_Eye_2023_Gerosolima.pdf (1.5 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04328544 , version 1 (07-12-2023)

Licence

Identifiants

Citer

Maria Vittoria Cicinelli, Claudia Gerosolima, Pierluigi Scandale, Sarah Touhami, Dominika Pohlmann, et al.. Clinical and imaging biomarkers of response to intravitreal dexamethasone implant in eyes with non-infectious uveitic macular oedema. Eye, 2023, ⟨10.1038/s41433-023-02802-7⟩. ⟨hal-04328544⟩

Collections

U1219
11 Consultations
19 Téléchargements

Altmetric

Partager

More